Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 267 Results

July 28, 2026

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer

July 16, 2026

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

June 29, 2026

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

June 11, 2026

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

May 28, 2026

Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference

May 12, 2026

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 6, 2026

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

May 5, 2026

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026

March 19, 2026

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

March 12, 2026

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

12 3 4 5 6...»

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top